Yunlong Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunlong Lu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Wukun Liu
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization School of Medicine Nanjing University of Chinese Medicine Nanjing P. R. China
9 shared publications Lijuan Liu
School of Medicine
3 shared publicationsTianpeng Zheng
School of Medicine
3 shared publicationsZhenfan Wen
School of Medicine
3 shared publicationsZhenlin Liang
School of Medicine
3 shared publicationsFeiwan Zou
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China
2 shared publications
Latest Publications
- 30 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16363-16380
Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway
Endocrine resistance remains a major obstacle in the effective treatment of hormone-receptor-positive breast cancer. ESR1 mutations, such as Y537S and D538G, are commonly considered to confer such resistance. It is necessary to develop novel therapeutic agents to overcome endocrine resistance. Herein, we developed drug-conjugated Tam-NHC-gold(I) complexes that can target breast cancer cells by the binding of tamoxifen (Tam) to the G protein-coupled estrogen receptor (GPER) present on cell membranes. The privileged complex, 7b, can significantly downregulate ER, inhibit ER downstream signaling pathways, and induce damage-associated molecular pattern (DAMP)-mediated immunogenic cell death (ICD). Mechanistically, RNA-sequencing analysis revealed that 7b can overcome mutant MCF-7Y537S resistance through the RAMP3/CALCR signaling pathway. Moreover, 7b exhibited potent antiproliferative activity on both wild-type and mutant MCF-7Y537S in xenograft mouse models with low toxicity. This study verified that 7b may offer a new approach for the treatment of endocrine-resistant breast cancer.
- 30 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16363-16380
Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway
Endocrine resistance remains a major obstacle in the effective treatment of hormone-receptor-positive breast cancer. ESR1 mutations, such as Y537S and D538G, are commonly considered to confer such resistance. It is necessary to develop novel therapeutic agents to overcome endocrine resistance. Herein, we developed drug-conjugated Tam-NHC-gold(I) complexes that can target breast cancer cells by the binding of tamoxifen (Tam) to the G protein-coupled estrogen receptor (GPER) present on cell membranes. The privileged complex, 7b, can significantly downregulate ER, inhibit ER downstream signaling pathways, and induce damage-associated molecular pattern (DAMP)-mediated immunogenic cell death (ICD). Mechanistically, RNA-sequencing analysis revealed that 7b can overcome mutant MCF-7Y537S resistance through the RAMP3/CALCR signaling pathway. Moreover, 7b exhibited potent antiproliferative activity on both wild-type and mutant MCF-7Y537S in xenograft mouse models with low toxicity. This study verified that 7b may offer a new approach for the treatment of endocrine-resistant breast cancer.
- 17 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 176, 109884
Discovery and development of the preclinical candidate (SH-1092), a potent third generation EGFR inhibitor for the treatment of NSCLC
- 17 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 176, 109884
Discovery and development of the preclinical candidate (SH-1092), a potent third generation EGFR inhibitor for the treatment of NSCLC
- 12 June 2025
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36 (10)
Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
- 12 June 2025
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36 (10)
Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
- 19 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (5) , 5275-5291
Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4
Gefitinib exhibits significant clinical efficacy in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitive mutations. However, its efficacy is severely limited by acquired resistance. Herein, we designed and synthesized a series of dual-targeting thioredoxin reductase (TrxR)-EGFR gold complexes by attaching a gold ligand to the parent structure of gefitinib, 4-anilinoquinazoline. Among them, L1Au2 exhibited significant activity against both gefitinib-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. Mechanistically, L1Au2 effectively inhibits TrxR and EGFR both in vitro and in vivo. Additionally, L1Au2 promotes the degradation of GPX4 protein via autophagolysosomal and proteasomal pathways, leading to ferroptosis. Notably, L1Au2 also induces endoplasmic reticulum stress (ERS) and triggers immunogenic cell death (ICD). In conclusion, this study provides an innovative strategy for overcoming gefitinib resistance in lung cancer by utilizing dual-targeting TrxR-EGFR alkynyl-Au(I) gefitinib derivatives, thereby offering a new approach for treating gefitinib-resistant lung cancer.
- 19 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (5) , 5275-5291
Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4
Gefitinib exhibits significant clinical efficacy in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitive mutations. However, its efficacy is severely limited by acquired resistance. Herein, we designed and synthesized a series of dual-targeting thioredoxin reductase (TrxR)-EGFR gold complexes by attaching a gold ligand to the parent structure of gefitinib, 4-anilinoquinazoline. Among them, L1Au2 exhibited significant activity against both gefitinib-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. Mechanistically, L1Au2 effectively inhibits TrxR and EGFR both in vitro and in vivo. Additionally, L1Au2 promotes the degradation of GPX4 protein via autophagolysosomal and proteasomal pathways, leading to ferroptosis. Notably, L1Au2 also induces endoplasmic reticulum stress (ERS) and triggers immunogenic cell death (ICD). In conclusion, this study provides an innovative strategy for overcoming gefitinib resistance in lung cancer by utilizing dual-targeting TrxR-EGFR alkynyl-Au(I) gefitinib derivatives, thereby offering a new approach for treating gefitinib-resistant lung cancer.
- 6 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (2) , 1002-1020
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
The lysine acetyltransferase 6A (KAT6A, MOZ, MYST3) is a member of the MYST family of protein acetyltransferases, which are essential for different biological processes such as craniofacial, embryonic, stem cell development, and hematopoiesis. KAT6A is an oncogene in human acute myeloid leukemia (AML), and KAT6A overexpression in AML is associated with metastases and poor prognoses. Furthermore, KAT6A mutations play an important role in cancer formation and progression and result in therapeutic resistance in both hematopoietic malignancies and solid tumors. In this review, we discuss the structural and biological functions of KAT6A and summarize the influence of KAT6A in the development of various tumors. In addition, the recent KAT6A/B inhibitors, their anticancer activities, challenges, and perspective of developing KAT6A/B inhibitors as anticancer drug candidates were introduced.
- 6 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (2) , 1002-1020
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
The lysine acetyltransferase 6A (KAT6A, MOZ, MYST3) is a member of the MYST family of protein acetyltransferases, which are essential for different biological processes such as craniofacial, embryonic, stem cell development, and hematopoiesis. KAT6A is an oncogene in human acute myeloid leukemia (AML), and KAT6A overexpression in AML is associated with metastases and poor prognoses. Furthermore, KAT6A mutations play an important role in cancer formation and progression and result in therapeutic resistance in both hematopoietic malignancies and solid tumors. In this review, we discuss the structural and biological functions of KAT6A and summarize the influence of KAT6A in the development of various tumors. In addition, the recent KAT6A/B inhibitors, their anticancer activities, challenges, and perspective of developing KAT6A/B inhibitors as anticancer drug candidates were introduced.
- 21 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 279, 116897
Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant
- 21 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 279, 116897
Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant
- 31 March 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 34 (9) , 108413
NHC-gold(I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system
- 31 March 2023
- Published by Elsevier in Chinese Chemical Letters
- Vol. 34 (9) , 108413
NHC-gold(I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system
- Top Cited Papers
- 14 June 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (13) , 5518-5556
Recent development of gold( i ) and gold( iii ) complexes as therapeutic agents for cancer diseases
Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.
- 14 June 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (13) , 5518-5556
Top Cited PapersRecent development of gold( i ) and gold( iii ) complexes as therapeutic agents for cancer diseases
Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.
- 29 May 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 98 (3) , 435-444
Synthesis andin vitroanticancer activities of seleniumN‐heterocyclic carbene compounds
Fourteen novel seleniumN‐heterocyclic carbene (Se‐NHC) compounds derived from 4,5‐diarylimidazole were designed, synthesized, and evaluated as antiproliferative agents. Most of them were more effective toward A2780 ovarian cancer cells than HepG2 hepatocellular carcinoma cells. Among them, the most active compound2bwas about fourfold more active than the positive control ebselen against A2780 cells. In addition, this compound displayed twofold higher cytotoxicity to A2780 cells than to IOSE80 normal ovarian epithelial cells. Further studies revealed that2bcould induce reactive oxygen species production, damage mitochondrial membrane potential, block the cells in the G0/G1 phase, and finally promote A2780 cell apoptosis.
- 29 May 2021
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 98 (3) , 435-444
Synthesis andin vitroanticancer activities of seleniumN‐heterocyclic carbene compounds
Fourteen novel seleniumN‐heterocyclic carbene (Se‐NHC) compounds derived from 4,5‐diarylimidazole were designed, synthesized, and evaluated as antiproliferative agents. Most of them were more effective toward A2780 ovarian cancer cells than HepG2 hepatocellular carcinoma cells. Among them, the most active compound2bwas about fourfold more active than the positive control ebselen against A2780 cells. In addition, this compound displayed twofold higher cytotoxicity to A2780 cells than to IOSE80 normal ovarian epithelial cells. Further studies revealed that2bcould induce reactive oxygen species production, damage mitochondrial membrane potential, block the cells in the G0/G1 phase, and finally promote A2780 cell apoptosis.